激活转录因子3是连接肝脂肪变性与糖稳态受损的靶分子
在ZDF大鼠及活检证实的NAFLD人群中,肝脏ATF3表达升高与肝脂肪变性、胰岛素抵抗及T2D替代标志物正相关;体内沉默ATF3可减轻大鼠肝脂肪变性、胰岛素抵抗和糖耐量异常。
要点
- ZDF大鼠和NAFLD和/或T2D患者肝脏ATF3高表达
- 体内沉默ATF3可减轻ZDF大鼠肝脂肪变性、胰岛素抵抗和炎症反应
- 肝ATF3表达与T2D替代标志物、线粒体功能障碍和巨噬细胞浸润正相关
核心结论
- 肝脏ATF3表达升高与肝脂肪变性及新发T2D密切相关,ATF3可能作为NAFLD和肝脂肪变性诱导T2D的潜在治疗靶点。
研究设计与样本
- 动物实验采用ZDF大鼠,通过体内jetPEI siRNA递送系统针对ATF3进行功能缺失实验。
- 横断面分析来自活检证实的NAFLD注册研究(n=322)的基线数据。
- 人类血清和肝组织来自43例活检证实的NAFLD患者和7名健康参与者。
主要发现
- ATF3在ZDF大鼠肝脏及NAFLD和/或T2D人类参与者中高表达。
- 胰岛素抵抗和肝脂肪变性与ATF3表达增加及线粒体功能障碍所致脂肪酸氧化减少相关,并被体内ATF3沉默所减轻。
- 敲低ATF3还改善了ZDF大鼠的糖耐量异常、胰岛素作用受损和炎症反应。
- 在NAFLD和/或T2D患者中,肝脏ATF3表达与T2D替代标志物、线粒体功能障碍和巨噬细胞浸润呈显著正相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) contributes to impaired glucose tolerance, leading to type 2 diabetes (T2D); however, the precise mechanisms and target molecules that are involved remain unclear. Activating transcription factor 3 (ATF3) is associated with β-cell dysfunction that is induced by severe stress signals in T2D. We aimed to explore the exact functional role of ATF3 as a mechanistic link between hepatic steatosis and T2D development. METHODS: Zucker diabetic fatty (ZDF) rats were utilized for animal experiments. An in vivo-jetPEI siRNA delivery system against ATF3 was used for loss-of-function experiments. We analyzed the baseline cross-sectional data derived from the biopsy-proven NAFLD registry (n=322). Human sera and liver tissues were obtained from 43 patients with biopsy-proven NAFLD and from seven healthy participants. RESULTS: ATF3 was highly expressed in the livers of ZDF rats and in human participants with NAFLD and/or T2D. Insulin resistance and hepatic steatosis were associated with increased ATF3 expression and decreased fatty acid oxidation via mitochondrial dysfunction and were attenuated by in vivo ATF3 silencing. Knockdown of ATF3 also ameliorated glucose intolerance, impaired insulin action, and inflammatory responses in ZDF rats. In patients with NAFLD and/or T2D, a significant positive correlation was observed between hepatic ATF3 expression and surrogate markers of T2D, mitochondrial dysfunction, and macrophage infiltration. CONCLUSIONS: Increased hepatic ATF3 expression is closely associated with hepatic steatosis and incident T2D; therefore, ATF3 may serve as a potential therapeutic target for NAFLD and hepatic steatosis-induced T2D. LAY SUMMARY: Hepatic activating transcription factor 3 (ATF3) may play an important role in oxidative stress-mediated hepatic steatosis and the development of type 2 diabetes (T2D) in a Zucker diabetic fatty (ZDF) rat model and in human patients with non-alcoholic fatty liver disease (NAFLD). Therefore, ATF3 may be a useful biomarker for predicting the progression of NAFLD and the development of T2D. Furthermore, given the significant association between hepatic ATF3 expression and both hepatic steatosis and impaired glucose homeostasis, in vivo ATF3 silencing may be a potential central strategy for preventing and managing NAFLD and T2D.
引用
- Kim JY, Park KJ, Hwang JY, et al. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis. J Hepatol. 2017. PMID: 28365312. doi:10.1016/j.jhep.2017.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。